Green Synthesized Ag Nanoparticles as Promising Antibacterial and Antitumor Agents: In Vitro Studies

绿色合成的银纳米粒子作为有前景的抗菌和抗肿瘤剂:体外研究

阅读:1

Abstract

In this work, we used a biocompatible and safe approach for the treatment of health-threatening diseases using the Spinacia oleracea plant. Practically, Ag nanoparticles were green synthesized applying Spinacia oleracea to use against breast cancer cells (MCF-7 and MDA-MB-231 cell lines) and bacteria (S. aureus, S. epidermidis, and P. aeruginosa). Next, analytical techniques (FT-IR, XRD, DLS, TEM, and SEM) were employed for the characterization of nanoparticles. Nanometric size (10 nm to 25 nm in diameter), crystallinity, and spherical and semi-spherical morphology were determined for the biosynthesized Ag nanoparticles. Then, several biomedical tests (MIC, MBC, cell viability (MTT), quantitative gene expression (qRT-PCR), cell cycle arrest, and apoptosis) were performed for investigating the cell suppression capability of Ag nanoparticles and extracted plant precursor. These results indicated MIC of 20 nM, 35 nM, and 35 nM for S. epidermidis, P. aeruginosa, and S. aureus after treatment with Ag nanoparticles, respectively. Cell viabilities of 35% to 90% (for plant precursor) and 55% to 85% (for Ag nanoparticles) were observed for both cancer cells. Expression levels of BRCA1 (3 to 6 folds decrease), BRCA2 (4 to 15 folds decrease), Caspase9 (3.5 folds increase), Bcl2 (3 folds decease), Beclin1 (no considerable shift), and ATG (1.3 folds increase) genes were ascertained in cancer cells after treatment with Ag nanoparticles. Also, the cell cycle arrest (18- and 19-fold increase for MCF-7 and MDA-MB-231, respectively) and apoptosis (22% necrosis for MCF-7 and 17.5% apoptosis for MDA-MB-231) assays have remarkably confirmed the potency of biosynthesized Ag nanoparticles in the treatment of diseases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。